ICYMI: Positive Topline Data Available on Vimseltinib for TGCT
Surgical resection remains the most common treatment approach for people living with tenosynovial giant cell tumors (TGCT). Unfortunately, surgery is not always an appropriate
TGCT Support
TGCT Support
Previously known as pigmented villonodular synovitis (PVNS) and giant cell tumor of the tendon sheath (GCT-TS), Tenosynovial Giant Cell Tumor (TGCT) is a type of rare, locally aggressive, typically benign, tumor of the joint, tendon sheath, or bursae.
TGCT Support is a community open to TGCT patients, their caregivers and family members. It is also open to physicians, researchers, and others interested in learning more about TGCT and helping those with the disease. Joining the community is free! We want to come together to share medical experiences, provide each other with support, and share tools to guide you through your TGCT journey. Most importantly, we are here to ensure that no one faces TGCT alone.
Learn more: [email protected]
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Resources & Support
Patient Worthy Posts on TGCT
Rare Classroom: Tenosynovial Giant Cell Tumor
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on
Making History: First Treatment for TGCT Gets FDA Approved
According to a story from fda.gov, the US Food and Drug Administration (FDA) has approved the drug pexidartinib (marketed as Turalio) as a treatment for
Positive Data from Phase 3 Trial for Potential TGCT Treatment
According to a story from BioSpace, the drug developer Daiichi Sankyo Company Limited has recently announced positive data resulting from a pooled anaylsis of a
